|
US4328245A
(en)
|
1981-02-13 |
1982-05-04 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
US4410545A
(en)
|
1981-02-13 |
1983-10-18 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
US4409239A
(en)
|
1982-01-21 |
1983-10-11 |
Syntex (U.S.A.) Inc. |
Propylene glycol diester solutions of PGE-type compounds
|
|
US4911920A
(en)
|
1986-07-30 |
1990-03-27 |
Alcon Laboratories, Inc. |
Sustained release, comfort formulation for glaucoma therapy
|
|
FR2588189B1
(fr)
|
1985-10-03 |
1988-12-02 |
Merck Sharp & Dohme |
Composition pharmaceutique de type a transition de phase liquide-gel
|
|
JP2594486B2
(ja)
|
1991-01-15 |
1997-03-26 |
アルコン ラボラトリーズ インコーポレイテッド |
局所的眼薬組成物
|
|
US5212162A
(en)
|
1991-03-27 |
1993-05-18 |
Alcon Laboratories, Inc. |
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
|
|
KR19990067704A
(ko)
|
1992-12-17 |
1999-08-25 |
디. 제이. 우드, 스피겔 알렌 제이 |
부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
|
|
JPH0971528A
(ja)
*
|
1995-07-05 |
1997-03-18 |
Hayashibara Biochem Lab Inc |
抗腫瘍剤
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
AU713673B2
(en)
|
1996-02-07 |
1999-12-09 |
Neurocrine Biosciences Inc. |
Pyrazolopyrimidines as crf receptor antagonists
|
|
DE69720965T2
(de)
|
1996-02-13 |
2004-02-05 |
Astrazeneca Ab |
Chinazolinderivate und deren verwendung als vegf hemmer
|
|
NZ331191A
(en)
|
1996-03-05 |
2000-03-27 |
Zeneca Ltd |
4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
|
|
HU229024B1
(en)
|
1996-07-24 |
2013-07-29 |
Bristol Myers Squibb Pharma Co |
Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
|
|
JP3621706B2
(ja)
|
1996-08-28 |
2005-02-16 |
ファイザー・インク |
置換された６，５―ヘテロ―二環式誘導体
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
GB9714249D0
(en)
|
1997-07-08 |
1997-09-10 |
Angiogene Pharm Ltd |
Vascular damaging agents
|
|
IL137019A
(en)
|
1998-01-28 |
2010-11-30 |
Du Pont Pharm Co |
2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them
|
|
GB9900334D0
(en)
|
1999-01-07 |
1999-02-24 |
Angiogene Pharm Ltd |
Tricylic vascular damaging agents
|
|
GB9900752D0
(en)
|
1999-01-15 |
1999-03-03 |
Angiogene Pharm Ltd |
Benzimidazole vascular damaging agents
|
|
EP1040831A3
(en)
|
1999-04-02 |
2003-05-02 |
Pfizer Products Inc. |
Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
|
|
AU4203500A
(en)
|
1999-04-06 |
2000-10-23 |
Du Pont Pharmaceuticals Company |
Pyrazolopyrimidines as crf antagonists
|
|
FR2796380B3
(fr)
|
1999-07-15 |
2001-08-17 |
Sanofi Synthelabo |
Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
|
|
ES2277855T3
(es)
|
1999-09-30 |
2007-08-01 |
Neurogen Corporation |
Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas.
|
|
PL351069A1
(en)
|
1999-12-08 |
2003-03-10 |
Pharmacia Corp |
Valdecoxib compositions
|
|
AU2001258628A1
(en)
|
2000-05-31 |
2001-12-11 |
Astrazeneca Ab |
Indole derivatives with vascular damaging activity
|
|
MXPA02012905A
(es)
|
2000-07-07 |
2004-07-30 |
Angiogene Pharm Ltd |
Derivados de colquinol como agentes de dano vascular..
|
|
MXPA02012903A
(es)
|
2000-07-07 |
2004-07-30 |
Angiogene Pharm Ltd |
Derivados de colquinol como inhibidores de angiogenesis.
|
|
NZ528207A
(en)
|
2001-03-13 |
2006-02-24 |
Bristol Myers Squibb Pharma Co |
4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-A]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
|
|
US20050085479A1
(en)
|
2003-08-27 |
2005-04-21 |
Pharmacia Corporation |
Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
|
|
EP1708790B1
(en)
|
2003-12-02 |
2010-04-21 |
PharmaNeuroBoost N.V. |
Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
|
|
MY143499A
(en)
|
2003-12-22 |
2011-05-31 |
Sb Pharmco Inc |
Crf receptor antagonist and methods relating thereto
|
|
WO2005079807A1
(en)
|
2004-02-13 |
2005-09-01 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
|
|
EP1722826A2
(en)
|
2004-02-13 |
2006-11-22 |
SB Pharmco Puerto Rico Inc. |
Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses
|
|
EP1781257B1
(en)
|
2004-08-13 |
2018-12-19 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
|
EP1869049B1
(en)
|
2005-03-21 |
2009-03-04 |
Eli Lilly And Company |
Imidazopyridazine compounds
|
|
EP2004205A4
(en)
*
|
2006-03-29 |
2010-06-09 |
Velacor Therapeutics Pty Ltd |
INORGANIC SELEN FOR THE TREATMENT OF GOOD TUMORS
|
|
CN101516835A
(zh)
|
2006-07-19 |
2009-08-26 |
俄亥俄州立大学研究基金会 |
选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途
|
|
JP5184536B2
(ja)
|
2006-09-20 |
2013-04-17 |
イーライ リリー アンド カンパニー |
チオフェンピラゾロピリミジン化合物
|
|
HRP20100516T1
(hr)
*
|
2006-09-20 |
2010-10-31 |
Eli Lilly And Company |
Tiazolpirazolopirimidini kao antagonisti receptora crf1
|
|
US8952207B2
(en)
|
2007-09-11 |
2015-02-10 |
The University Of Houston System |
Copper-catalyzed C—H bond arylation
|
|
US8318813B2
(en)
|
2007-09-13 |
2012-11-27 |
Lcs Group, Llc |
Method of treating binge eating disorder
|
|
US20100203048A1
(en)
*
|
2008-04-30 |
2010-08-12 |
Stephen Evans-Freke |
Methods of using corticotropin-releasing factor for the use of the treatment of cancer
|
|
DK2350079T3
(da)
|
2008-10-02 |
2012-12-17 |
Lilly Co Eli |
Thiazolylpyrazolopyrimidinforbindelser som syntetiske mellemprodukter og dertil relaterede syntetiske fremgangsmåder
|
|
EP4718074A2
(en)
|
2008-12-24 |
2026-04-01 |
Quest Diagnostics Investments Incorporated |
Mass spectrometry assay for congenital adrenal hyperplasia
|
|
EP2682111A1
(en)
|
2009-12-31 |
2014-01-08 |
Differential Drug Development Associates LLC |
Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
|
|
AU2013230781B2
(en)
|
2012-03-08 |
2015-12-03 |
Medtronic Af Luxembourg S.A.R.L. |
Ovarian neuromodulation and associated systems and methods
|
|
US20150094310A1
(en)
|
2012-04-23 |
2015-04-02 |
Holsboermaschmeyer Neurochemie Gmbh |
Crhr1 antagonists for use in the treatment of patients having crh overactivity
|
|
RS65839B1
(sr)
|
2014-01-21 |
2024-09-30 |
Neurocrine Biosciences Inc |
Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije
|
|
AU2016242867B2
(en)
|
2015-03-31 |
2020-11-05 |
May Health Us Inc. |
Methods and systems for the manipulation of ovarian tissues
|
|
WO2019036503A1
(en)
|
2017-08-14 |
2019-02-21 |
Spruce Biosciences, Inc. |
CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
|
|
JP7285222B2
(ja)
|
2017-08-14 |
2023-06-01 |
スプルース バイオサイエンシズ インコーポレイテッド |
副腎皮質刺激ホルモン放出因子受容体拮抗薬
|
|
EP4643950A3
(en)
|
2018-04-27 |
2026-01-14 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
|
US20220023266A1
(en)
|
2018-12-07 |
2022-01-27 |
Neurocrine Biosciences, Inc. |
Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
|
|
US20200255436A1
(en)
|
2019-02-12 |
2020-08-13 |
Spruce Biosciences, Inc. |
Corticotropin releasing factor receptor antagonists
|
|
JP2022541550A
(ja)
|
2019-07-19 |
2022-09-26 |
スプルース バイオサイエンシーズ，インク． |
先天性副腎過形成を処置する方法
|
|
KR20240023691A
(ko)
|
2020-08-12 |
2024-02-22 |
스프루스 바이오사이언시스 인코포레이티드 |
다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
|
|
JP2024539907A
(ja)
|
2021-11-19 |
2024-10-31 |
スプルース バイオサイエンシーズ，インク． |
チルダセルフォントの結晶性組成物ならびにその使用方法および調製方法
|
|
US11708372B2
(en)
|
2021-11-19 |
2023-07-25 |
Spruce Biosciences, Inc. |
Crystalline composition of tildacerfont and methods of use and preparation thereof
|